Mohamed A, et al. - Researchers compared weekly to triweekly cisplatin regarding efficacy and safety in locally advanced squamous cell carcinoma of the head and neck. In this systemic review, they included 39 (18 weekly, 21 triweekly) prospective studies with 3668 patients from 1500 prospective studies published from 1970 to 2015. Outcomes suggest that efficacy and safety of weekly cisplatin were comparable to that of the triweekly regimen. With tolerability being a key factor in selection, the use of weekly or triweekly cisplatin is supported in locally advanced squamous cell carcinoma of the head and neck.